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The demonstration of the central role of the 
mobile pool of ubiquinone as the link between the 
flavin- and cytochrome-containing sectors of the 
respiratory chain raised the possibilities of the ex- 
istence of coenzyme Q-deficiency states and of the 
therapeutic benefits of its exogenous administra- 
tion. Ubiquinone may be endogenously synthesis- 
ed, but, then, this is also the case for vitamin D 
. . . . The High Priest of such speculation was Karl 
Folkers at the Institute for Biomedical Research in 
Austin, Texas, where he carried out his first 
clinical experiment 20 years ago. The movement 
gradually gained momentum, fuelled by such in- 
triguing questions as the role of the significant 
amounts of ubiquinone found in cellular loci other 
than the inner mitochondrial membrane, and 
perhaps by analogy with the Pauling-led vitamin C 
bonanza. 
The number of ‘the faithful’ (to use Folkers’ 
term) grew, both among basic biochemists and 
clinicians, particularly in Japan where a major act 
of faith was the investment by the Japanese phar- 
maceutical industry in the production of coenzyme 
Q on a scale sufficient not only to support the 
burgeoning research interest, but also clinical trials 
and, now, routine prescription. 
These developments were recorded in Interna- 
tional Symposia on Biomedical and Clinical 
Aspects of Coenzyme Q held in Japan in 1976 and 
1979. The present volume reports the third such 
meeting, this time held at Austin. 
As is inevitable in the case of a drug looking for 
a disease the content is somewhat diffuse. When 
the topic is clearly defined, some of the papers are 
excellent, as on the production of coenzyme Q by 
partial synthesis or by fermentation or on 
analytical methods for determining tissue levels. At 
the level of basic biochemistry too there are 
notable contributions by such luminaries as 
Mitchell, King, Ranganathan, Lenaz, Crane and 
Ernster. However, some of the other sessions, on 
oral disease, diseases of muscle, the immune 
system and ageing, model systems (emphasising 
ischaemia) and treatment of cardiovascular disease 
are patchy, and some of the clinical work is, frank- 
ly, unconvincing. The systems chosen sometimes 
reflect the clinical interests of the investigator 
rather than any logical deduction about tissue- 
specific roles for coenzyme Q. 
Nevertheless oms good model systems are being 
developed and some relevant parameters of cardiac 
function are being defined. There is also persuasive 
evidence that exogenous coenzyme Q might fulfil a 
valuable antioxidant function in protecting against 
the toxic side effects of anti-cancer drugs such as 
adriamycin. It is also reassuring to note that, in 
spite of hypothetical pathological effects of treat- 
ment with ubiquinone (the semiquinone of which is 
a potential generator of oxygen radicals), as 
discussed in a cautionary paper by Demopoulos 
and Flamm, the drug has been on the market in 
Japan since 1974 with no reported toxicity. 
Overall, the Symposium was undoubtedly 
stimulating, and in spite of the uneven and 
sometimes evangelical character of the book it 
must be an essential reference for anyone in- 
terested in this speculative but expanding and in- 
triguing field. 
H. Baum 
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